Skip to main content

Table 1 Study schedule. MADRS and HAM-D at V0 are part of usual care of the included patients

From: Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)

Criteria Selection: Psychiatry consultation or hospitalization Visit V0: Psychiatry 0–20 days after decision of drug dosage increase Visit V1: With a nurse Period: 7–21 days after V0 Visit V2: With a Psychologist or a pratictionner: 25–40 days (4 weeks) after V0 Visit V3: With a Psychologist or a pratictionner: 50–70 days (8 weeks) after V0
Oral and written Information about the protocol MARVEL MARVEL    
Verification of inclusion and non inclusion criteria, Signature of informed consent MARVEL MARVEL    
MADRS and HAM-D   Usual care   MARVEL MARVEL
Screen for tobacco use   MARVEL    
Renal and liver function   MARVEL    
Characteristics of the mood disorder   MARVEL    
Anxiety scale Tyrer   MARVEL    
Criteria for rating medication trials for antidepressant failure   MARVEL    
QIDS-score   MARVEL   MARVEL MARVEL
MARS score   MARVEL   MARVEL MARVEL
PRISE-M score   MARVEL   MARVEL MARVEL
FIBSER score   MARVEL   MARVEL MARVEL
Urinary pregnancy test    MARVEL   
Current treatment   MARVEL MARVEL MARVEL MARVEL
Recent alimentation    MARVEL   
Blood sample for Css of V and ODV, and mRNA    MARVEL   
Cocktail of drugsa administration    MARVEL   
Blood sample for Phenotypic study    MARVEL   
Total amount of blood for the research Visit 1 only: 12.5 mL of venous blood and 3 drops of capillary blood sample
  1. afexofenadine, midazolam, dextromethorphan, omeprazole
  2. MADRS (Montgomery and Asberg Depression Rating Scale), HAM-D (Hamilton Rating Scale for Depression), QIDS (Quick Inventory of Depressive Symptomatology), MARS (score Medication Adherence Report Scale), PRISE-M (Patient Rated Inventory of Side Effects), FIBSER (Frequency, Intensity, and Burden of Side Effects Ratings), V (Venlafaxine), ODV (O-demethyl-Venlafaxine)